Top 50 Life Science VC (Venture Capital) Funds in Switzerland in October 2024
A list of 50 VC (Venture Capital) funds that invest in Life science startups based in Switzerland. We rank investors based on the number of investments they made in Life science companies from Switzerland. We update this investor list every month.Top 50 Life Science VC (Venture Capital) Funds in Switzerland in October 2024
Zürcher Kantonalbank - as an independent, incorporated public-law institution - is wholly owned by the canton of Zurich.
Show more
Investment focus
- Health Care, Medical Device, Biotechnology
- Seed, Series A, Funding Round
- Switzerland, Japan, Spain
Portfolio highlights
- DataHow — DataHow is specialized in data analytics and bioprocess modeling
- Drone Harmony AG — Drone Harmony was founded in 2016 by a team of problem solvers with a passion for drones, software and automation. From their very early days, they have set out to tackle the mathematical and engineering challenges of enabling cost-effective deployment of drone technology in industries, where existing technologies were unable to deliver.DroneHarmony reinvents the way people fly drones commercially. Its 3D flight planning software turns anyone with a drone into an inspection professional. Sophisticated algorithms reduce complex industrial inspection tasks to automated and scalable workflows.
- Synthara Technologies — Synthara is a Zurich-based artificial intelligence (AI) company that provides system-level solutions for businesses to enhance their products or services with smart features. The company portable and wearable gadgets such as virtual reality headsets, small wireless monitoring cameras, sensor networks, have limited smart features because computingpowerful algorithms cannot be run on them. Synthara IPs provide server-class performance with an extremely low energy requirement for neural networks (10 TOPs/Watt).
Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up
Show more
Investment focus
- Biotechnology, Pharmaceutical, Health Care
- Seed, Series C, Funding Round
- Switzerland
Portfolio highlights
- KYLYS — KYLYS is an innovative Swiss company based in Geneva founded in March 2017. KYLYS provides people and patients with highly effective and safe products based on biomolecules.
- Genkyotex — Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
- MPC Therapeutics — MPC Therapeutics develops a novel class of compounds with application in Immunotherapy and Metabolic diseases
The Foundation for Technology Innovation gives financial assistance to creative and technological projects at various phases of development. FIT funds projects in energy and the environment, information and digital technology, life sciences and health, precision industries, and nutrition and agriculture.
Show more
Investment focus
- Health Care, Biotechnology, Software
- Debt Financing, Grant, Seed
- Switzerland, France
Portfolio highlights
- Aspivix — ASPIVIX is developing a new generation of medical devices that make gynecological procedures gentler and safer for women and gynecologists. The first device, CAREVIX, is designed to prevent cervix bleeding using a suction technology to replace traumatic tenaculum (forceps).
- Xemperia — Xemperia provides diagnostic solutions that helps to detect breast cancer and early diagnosis of relapses.
- Ex Nunc Intelligence — Ex Nunc Intelligence provides professionals with thorough summaries of legal information, credible responses to legal issues, and automated legal document preparation features.
BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland.
BlueOcean Ventures is based in Geneva, Switzerland.
Show more
Investment focus
- Health Care, Medical, Biotechnology
- Series A, Seed, Series B
- Switzerland, India, France
Portfolio highlights
- nPloy — Simply set your filters and get matched with your dream job! Let top employers apply for you & connect with them via chat or a video call.
- CyanoGuard AG — Our award-winning cyanide testing and optimizing solution is ideal for the mining, food, and medical field. It's easy to use, digital and offers real-time data.
- 99RetailStreet — 99RetailStreet is an eCommerce Cloudplatform for the unorganized Retail business in the developing countries. Our ecosystem targets Retailers, Distributors, and Manufacturers. 99RetailStreet provides POS solutions to Retailers, Real-Time Analytics to Manufacturers and Distributors
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- United States, Switzerland, Canada
Portfolio highlights
- SixPeaks Bio — SixPeaks is developing a pipeline of medicines for healthy weight loss.
- Borealis Biosciences — Borealis Biosciences was founded on the premise that a convergence of scientific and translational breakthroughs is enabling the field of RNA medicines to treat kidney diseases and beyond. The company is backed by founding investor Versant Ventures and Novartis AG, and has a strategic collaboration with the pharma.
- Bright Peak Therapeutics — Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases. At Bright Peak, they are creating innovative cytokine therapeutics that are uniquely engineered to precisely control and expand desired biological properties.
Backing engineers building awe, wonder, speed.
Show more
Investment focus
- Software, Biotechnology, Health Care
- Pre-Seed, Seed, Funding Round
- United States, United Kingdom, France
Portfolio highlights
- Yakoa — Harness AI to detect and address infringements, effortlessly. Eliminate manual searches, experience ecosystem-wide forensics and Proactively screen violations.
- Modelwise — Automated functional safety analysis via drag & drop. Seamless Integration. Faster Analyses. Zero Defects. More Savings.
- Fluent Metal — Fluent Metal is a company that makes metal 3D printing economical, efficient, and safe.
Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.
Show more
Investment focus
- Health Care, Software, Biotechnology
- Series A, Seed, Series B
- Switzerland, Germany, France
Portfolio highlights
- Cubbit — Cubbit is secure encrypted cloud storage with a difference. A distributed cloud that is 100% private and green. Join the Swarm.
- Axelera AI — To accelerate computer vision in edge devices, we offer a powerful, energy-efficient, cost-effective, user-friendly AI hardware and software platform.
- Puraffinity — Puraffinity develops targeted materials for water treatment, focused on forever chemicals called PFAS. Our strategic intent is to provide 1 billion people with PFAS safe water by 2030
Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Funding Round, Series B, Series A
- Denmark, Sweden, Switzerland
Portfolio highlights
- Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
- Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
- Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- Switzerland, Germany, France
Portfolio highlights
- Tricares — TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.
- ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
- Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
Boosting health pioneers. We invest in early stage start-ups in different sectors: medtech, life science, biotech, mental health, public health, well-being.
Show more
Investment focus
- Medical, Health Care, Biotechnology
- Seed, Series A
- Switzerland
Portfolio highlights
- Healios AG — Healios CTMS provides the Digital Biomarker based technology and digital validation scales to improve and streamline research and clinical practice.
- Testmate Health — Testmate Health is a medtech startup and award-winning spin-off of University of Geneva (Switzerland). We have developed a smartphone compatible platform test kit that diagnoses any disease with an identifiable DNA or RNA sequence - without the need for a lab, providing results directly at home in minutes. Based on this platform, our firstsolution is the first rapid urine self-test for the four most common sexually transmitted diseases (STD). One million new STDs are diagnosed a day, and yet the best improvements to date still need a lab, with results taking up to 7 days to be ready. Our easy to use all-in-one-kit provides results in minutes, anywhere, at any time, and the result is scannable by a smartphone to enable people to immediately gain access to treatment – if needed. Further test-kits with other diseases are in the pipeline to empower users to skip the waiting room, and take charge of their health from home.
- Limula — Limula provides a unique platform technology enabling scale out of cell therapy production. By bringing manufacturing closer to the patients, our solution will broaden access to these highly personalised treatments. Our patented solution is composed of an automation unit and single use kits, allowing healthcare providers to safely manufacture CGTin a decentralized manner. We support companies at all stages of the cell therapy life cycle, from R&D to routine production.
Vinci Capital is a leading Swiss private equity firm with over MCHF 200 under management. Since 1998 they have provided equity to over 30 Swiss technology and industrial companies to finance innovation, growth and succession-buyouts.Their investment team capitalizes on 40 years of cumulated experience in private equity and a solid operationalbackground in growth, turn-around, consolidation, IPOs and M&A situations.
Show more
Investment focus
- Medical, Health Care, Biotechnology
- Series A, Series B, Funding Round
- Switzerland, Germany
Portfolio highlights
- Anergis — Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne inSwitzerland.
- SENSIMED — Sensimed designs, develops, and commercializes integrated micro-systems for medical devices. The company’s product portfolio includes SENSIMED Triggerfish, a product that offers an automated recoding of continuous ocular dimensional change over 24 hours. Sensimed is now focused on expanding the knowledge of how this individual data can best beused in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment.Sensimed was founded by Matteo Leonardi and Sacha Cerboni in August 2003 and is based in Lausanne, Switzerland.
- Beqom — beqom is a Total Compensation Management Software Solution focused exclusively on managing compensation & performance for HR & Sales.
EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Series C
- United States, The Netherlands, Switzerland
Portfolio highlights
- Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
- PanTera — PanTera wants to bring a new hope to cancer patients by enabling the widespread use of radiopharmaceuticals for personalised treatment of tumors
- Vico Therapeutics — Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.
Kinled was founded in 1980 to retain the investment assets of the Aisher family.In 1990, the investment focus shifted to a portfolio of early stage investments applying Kinled’s company development experience alongside the endurance and passion of family owned investments together with the strategic focus of venture capitalists.Since then,Kinled has taken 8 companies to public markets and many more to successful trade sales at significant multiples.
Show more
Investment focus
- Biotechnology, Health Care, Financial Services
- Seed, Funding Round, Series A
- United Kingdom, United States, Switzerland
Portfolio highlights
- Xapien — Xapien delivers automated insight reports on companies and individuals in minutes, so you can make informed business decisions quickly and with confidence.
- OneTrust — OneTrust is a provider of privacy management and marketing compliance technology that helps organizations comply with global regulations. It automates privacy impact assessments and data inventory mapping, enforces risk remediation actions, and triggers recurring audits for continuous compliance monitoring across customer, employee, and vendor datatransfers. Its web-based software can be accessed on any device and provides a single place for a private office to collaborate with business groups, vendors, and trusted advisors managing privacy risks. The result is the ability to demonstrate privacy by design and ongoing compliance with policies, data privacy laws (GDPR, BCR, Privacy Shield), and other privacy frameworks (HITECH, ISO, GAPP, APEC).The company was founded in 2016 and is headquartered in Atlanta, Georgia.
- Connect Earth — Connect Earth is an environmental data company that builds the infrastructure for climate-conscious products by aggregating and standardising environmental data and making it available through developer-first toolkits. The core product is an API solution that calculates the carbon impact of spend-based financial transactions of consumers and companies.
Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.
Show more
Investment focus
- Health Care, Medical, Biotechnology
- Seed, Series A, Series B
- Switzerland
Portfolio highlights
- EBAMed — EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
- Gmelius — Gmelius is the world's first 360 email collaboration platform designed for Gmail and your company's daily apps. Join the async movement!
- Annaida Technologies — Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates.
HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Seed, Convertible Note, Pre-Seed
- United States, India, United Kingdom
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Rheingau Founders is a Berlin&Munich based Venture Capital firm active since 2011. Focusing on pre-seed to Series A investments in Europe, predominantly B2B in the fields of Marketplaces, Software as a Service, InsurTech, and eHealth. Rheingau targets start-ups that have the potential to sustainably disrupt existing processes and value chains.Besides the financial investment, we offer strategic support through the mentorship of our partners.
Show more
Investment focus
- Software, E-Commerce, Internet
- Seed, Series A, Pre-Seed
- Germany, United States, Poland
Portfolio highlights
- NetBird — Wiretrustee is an open-source VPN platform built on top of WireGuard® making it easy to create secure private networks for your organization or home. It requires zero configuration effort leaving behind the hassle of opening ports, complex firewall rules, VPN gateways, and so forth.
- MoleQlar — MoleQlar is a data and research-driven longevity company. It provides valuable information and offers consumers lab-tested nutritional supplements. The company focuses on functional medicine with optimized nutrition. Their product range includes Uthever NMN, Resveratrol, Betaine, Carnosine, and more. These products are aimed at lowering biologicalage and promoting health and longevity. MoleQlar also offers health tracking services. The company is certified in Germany and delivers its products EU-wide, including Switzerland.
- Akhetonics — Creating the first all-optical RISC Processor
The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise,entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.
Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.
Show more
Investment focus
- Software, Information Technology, Biotechnology
- Seed, Series A, Funding Round
- Germany, Switzerland, United States
Portfolio highlights
- Samp — Samp accelerates modernization and de-risks contracts by connecting outdated drawings with current 3D reality captures of your facilities using our AI.
- become.1 — become.1 is an employee benefits platform that eliminates the complexity of tax regulations for employees.
- Symphera — An all-in-one surgical system that makes minimally-invasive procedures more efficient.
TiVenture is a seed investment fund owned by the Fondazione Centenario Banca Stato that invests in early stage companies with innovative technologies and high growth potential, principally in southern Switzerland. TiVenture is actively looking and ready to support exceptional founders and entrepreneurs developing scalable products for the globalmarket. TiVenture has a diversified portfolio of companies and is mainly active in the life science, medical, high-tech and IT sectors.
Show more
Investment focus
- Software, Analytics, Renewable Energy
- Seed, Series A, Funding Round
- Switzerland, Italy, United States
Portfolio highlights
- BigOmics — Get robust and reproducible results in a few clicks with Omics Playground: your user-friendly Omics Data Analysis Software.
- Hive Power — Hive Power provides a SaaS platform to optimise your existing electrical distribution grid, both from the technical and economic points of view.
- Gaia Turbine — Gaia Turbine SA - High-Performance Hydroelectric Turbine for micro and mini power plants
Bruker Corporation is a provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis.
Show more
Investment focus
- Biotechnology, Medical, Health Care
- Series A, Funding Round, Seed
- United States, Switzerland
Portfolio highlights
- KIYATEC — Kiyatec is a functional precision oncology company that measures the response of individual patient live cancer cells with its innovative 3D cell culture technology platform. Kiyatec works with leading biopharmaceutical companies to unlock response dynamics for investigational drug candidates for use in solid tumors.
- Haystack Oncology — Haystack Oncology, an oncology company, uses the most recent circulating tumor DNA detection technology to enhance the diagnosis of minimum residual disease and provide superior therapy decision-making information.
- Mercy BioAnalytics — We are making early stage cancer 100,000x easier to find using extracellular vesicles found in blood, specific to their parent cells.
Rhia Ventures invests in reproductive healthcare solutions that empower women.
Show more
Investment focus
- Health Care, Biotechnology, Women's
- Seed, Series A, Pre-Seed
- United States, Canada, Israel
Portfolio highlights
- Eli — Hormone testing redesigned so you can monitor anytime, anywhere.
- Contraline — Contraline is a medical device company that has developed a proprietary injectable hydrogel platform for use in reproductive and contraceptive applications. Contraline's first product, Adam, is implanted into the vas deferens through a minimally invasive, outpatient procedure and once implanted, the gel effectively blocks sperm. Adam isnon-hormonal, designed to last years, and easily reversible.
- Twentyeight Health — Your birth control. Delivered to your door. Get a new or re-up existing prescriptions, free & fast deliveries and follow up messaging with doctors. $0 with insurance and starting at $16/pack without.
Swiss ICT Investor Club (SICTIC) connects smart money investors to Swiss seed and early-stage tech startups.
Show more
Investment focus
- Software, Artificial Intelligence, Information Technology
- Seed, Pre-Seed, Funding Round
- Switzerland, Germany, United Kingdom
Portfolio highlights
- Pelt8 — Pelt8 enables climate action through the platform with scalable processes and controls to collect sustainability-related data in an easy and traceable way.
- Creaitor — Creaitor is the ultimate solution for content producers, offering a comprehensive suite of AI tools and integrated SEO features. Streamline your content creation process and optimize your online presence with our powerful platform.
- Health Yourself — Health Yourself is making routine healthcare services available digitally and from home. So far, we are offering lab tests from home, medication subscriptions and personalised supplements for health concerns ranging from sexual health to prevention.
We are a leading early-stage investment platform. We are at the center of a global ecosystem that attracts and fuels the technical founders and product teams building the next wave of global businesses.
Show more
Investment focus
- Software, Information Technology, Artificial Intelligence
- Seed, Series A, Pre-Seed
- United States, United Kingdom, France
Portfolio highlights
- Deta — The cloud for doers and dreamers
- AnySignal — AnySignal was developed to reimagine how RF capabilities are delivered for the most difficult tasks around the globe. offers complete solutions for modern aircraft, satellites, and national security that span communications, radar, navigation, and RF sensing. Current solutions are overpriced, unimaginative, and provide little end-to-end capability.To shift this paradigm, they are bringing the appropriate talent, procedures, and technologies together. They are developing communications systems for satellites, launchers, space stations, and aircraft. They provide full-stack connectivity solutions that include software modems, hardware for use in flight and on the ground, data management software, ground station integration software, and vehicle telemetry software.
- Harbinger — Founded by veterans of Canoo and Faraday Future, Harbinger is an automotive company that develops EV platforms optimized for medium-duty trucks and delivery vans.
Primal Capital, an independent venture capital " incubator bait fund at ", served as the Associate than July 2012 Hiroshi was Sasaki is the venture capital fund that serves as the representative partner. Representative of Sasaki, the seed acceleration program "Incubate Camp" operated by Incubate bait fund is carried out a totalof four times of planning and management than in 2012, They have also engaged in support operations of portfolio companies. - See more at: https://www.crunchbase.com/organization/primal-capital#sthash.m2z1DCbt.dpuf
Show more
Investment focus
- Information Technology, Software, Internet
- Seed, Funding Round, Pre-Seed
- Japan, Spain, Switzerland
Portfolio highlights
- Hivello — Hivello is a Decentralized Physical Infrastructure Network aggregator. Contribute resources, connect with Web3 protocols, and effortlessly generate passive income.
- RemitAid — RemitAid is a fintech company that operates an overseas payment platform for cross-border transactions between companies.
- xCARE — xCARE specializes in the development and commercialization phases of the pharmaceutical and medical device industries.
White Loop Capital is the first investment firm specialized in crypto-assets in France. Accompanying those who dare.
Show more
Investment focus
- Finance, Software, Life Science
- Seed, Pre-Seed, Funding Round
- Switzerland
Portfolio highlights
- Ondefy — Ondefy is building infrastructure that enables a simple access to decentralized finance. Integrate multiple DeFi services unders 1 line of code.
- DeepSquare — Managed, sustainable High Performance Computing as a Service. Decentralised. Community led. Blockchain (em)powered. DeepSquare solves real-world challenges facing intense computing demand. Combining traditional as a service business with blockchain, to deliver a transparent, fair trust-less ecosystem.
- Fluent — The Fluent network combines multiple tokens and offers unique market advantages compared to stablecoin competitors. Fluent is designed to be a true bridge between traditional finance and digital assets.
The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Seed
- United States, Germany, Belgium
Portfolio highlights
- Actym Therapeutics, Inc. — Actym Therapeutics is developing key biotech to help target intractable immune pathways in the tumor microenvironment.
- Glox Therapeutics — Developing novel precision antibiotics based on protein bacteriocins, to target Gram-negative Antimicrobial Resistant (AMR) pathogens.
- Asgard Therapeutics — Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biologicalproperties of professional antigen-presenting cells.
With more than 30 portfolio companies across AI, pet health, ageing medicine and more, LongeVC provides venture capital for the biotech and longevity sectors.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Seed, Funding Round, Series A
- United States, Estonia, Hong Kong
Portfolio highlights
- Melio — Melio has created a rapid, precise, and comprehensive blood test that identifies 99% of the most common pathogens in hours, rather than days.
- Catena Biosciences — Catena Biosciences uses a novel protein conjugation method to bring breakthroughs in biological therapeutics, autoimmune disorders and vaccine development
- Interface Biosciences — At the interface of Human Biology and AI
VI Partners are Venture Capitalists successfully financing outstanding teams and innovations in the Healthcare and Technology space since 20 years.
Show more
Investment focus
- Health Care, Biotechnology, Medical Device
- Series A, Series B, Series C
- Switzerland, Germany, United States
Portfolio highlights
- Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
- LeaseTeq — LeaseTeq bietet Privat- sowie Unternehmenskunden das erste komplett digitale Leasingangebot.
- Unique — Try Unique Finance GPT to increase productivity by automating manual workload through AI and ChatGPT solutions.
Recipharm Venture Fund is part of Recipharm AB.
Show more
Investment focus
- Biotechnology, Medical, Health Care
- Series A, Funding Round
- Sweden, Switzerland
Portfolio highlights
- NewBiologix — NewBiologix operates as a technology innovation company, develops a proprietary and breakthroughDNA integration platform for the advanced engineering of human and mammaliancell lines.
- Cinclus Pharma — A Swedish pharma company bringing relief to the world with the clinical stage drug candidate linaprazan glurate for gastric acid related diseases.
Gaingels is a leading venture investment syndicate in support of diversity, inclusive of the LGBTQIA+ community and allies in the venture capital space.
Show more
Investment focus
- Software, Health Care, FinTech
- Seed, Series A, Series B
- United States, Canada, Mexico
Portfolio highlights
- VerImmune — Located in Baltimore, Maryland, VerImmune is an Immuno-Oncology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection. This strategy utilizes a proprietary tumor-specific, tumor type agnostic, virus-inspired platform termed Anti-tumor Immune Redirection Virus-inspired Particles (AIR-ViPs) that redirectspre-existing pathogenic or childhood vaccine immune memory towards tumors.
- Permanent — Permanent grows, supplies, & distributes regenerative, organic, & differentiated produce. We optimize cost, quality, & impact for foodservice, CPG, & retail.
- Vahan.ai — Vahan uses Artificial Intelligence to match job seekers with employers inside messaging apps
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series A, Series B, Seed
- United States, Switzerland, United Kingdom
Portfolio highlights
- Anjuna — Anjuna confidential cloud software establishes a secure enclave that isolates and encrypts applications and data in runtime, at rest, and on the network for end-to-end data protection
- Formo — We're Formo, the future of dairy. Using micro fermentation, we create animal-free cheeses that humans love.
- NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
Privilege Ventures is the venture capital arm of Privilège Management and invest in seed and early stage companies. Geographical focus is Switzerland and the rest of Europe. Focus sectors are industrial-tech, med-tech, wearables and in general ICT.
Show more
Investment focus
- Health Care, Hardware, Software
- Seed, Series A, Funding Round
- Switzerland, France
Portfolio highlights
- Wyth — Wyth makes technologies that help humans create meaningful relationships by bringing emotions, stories and connections beyond the interface.
- Smeetz — Smeetz is the future of a unified, data-driven and dynamic pricing-oriented commerce for attractions and cultural venues.
- Avelo — Our mission is to save lives by bringing fast and actionable infectious disease diagnosis closer to the patient. Avelo's solution is a breath collection device. It works with existing molecular tests to detect multiple respiratory tract infections causing pneumonia
Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’spipeline and shape the future of its industry.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Series C
- United States, United Kingdom, Switzerland
Portfolio highlights
- Capstan Therapeutics — Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
- MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas
- Grey Wolf Therapeutics — By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the antigen repertoire in cancer.
Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.
Show more
Investment focus
- Health Care, Biotechnology, Pharmaceutical
- Series A, Series B, Seed
- France, Switzerland, Spain
Portfolio highlights
- SciRhom — SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academicand industry scientists with profound experience in antibody development.
- PanTera — PanTera wants to bring a new hope to cancer patients by enabling the widespread use of radiopharmaceuticals for personalised treatment of tumors
- Spotlight Medical — Spotlight Medical is a precision medicine company striving to free all patients from cancer through a better understanding of each patient’s unique disease. We develop advanced AI tests that enhance treatment selection by leveraging decades of patient data. This ensures personalized and effective care for each individual, significantly improvingpatient outcomes and quality of life. By closely collaborating with physicians, we create impactful tests that address critical unmet clinical needs, opening a new era in cancer care.
Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primaryinvestments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.
Show more
Investment focus
- Biotechnology, Health Care, Software
- Series B, Series A, Funding Round
- France, United States, Spain
Portfolio highlights
- Corti — Corti offers a digital assistant, augmenting medics in improving patient outcomes and internal performance.
- Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
- Stilla Technologies — Stilla Technologies is taking digital PCR to a whole new level with a unique 6-color target detection capability
A corporate venture investment company focussed on investing in mid to late stage clinical stage therapeutics development companies in North America and Europe
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Funding Round, Series A, Series B
- United Kingdom, Switzerland
Portfolio highlights
- Arquer Diagnostics — UroSens Ltd is based at the Babraham Research Campus, Cambridge, UK, and on the North East Business and Innovation Centre, Sunderland, UK.
- Versantis — Versantis is a Swiss pharmaceutical company, Spin-off of ETH Zurich, developing a new generation of medicines and diagnostics to revolutionize the care of patients with liver disease. Embracing lifesaving and preventive therapies, Versantis aims to answer the unmet medical need of millions of people worldwide. Its lead candidate, VS-01, iscurrently at preclinical stage and has the potential to be the first drug for acute liver disease simultaneously supporting multiple failing organs. VS-01 targets 3 rare indications and received an Orphan Drug Designation in ALF. In addition, Versantis’ pipeline promises to improve patients’ outcome in other medical fields; VS-02 and VS-03 are developed for chronic liver diseases and for the treatment of drug intoxications, both representing large market opportunities and significant upsides for Versantis.
- Amlo Biosciences — From ground-breaking research to revolutionary prognostics and diagnostics AMLo Biosciences is translating ground-breaking research in cancer biomarkers int ...
The UZH Life Sciences Fund involves two equal partners: the UZH Foundation and the Novartis Venture Fund. It seeks donations from private individuals, foundations and companies for the strategic priorities of the University of Zurich.
Show more
Investment focus
- Health Care, Biotechnology, Medical Device
- Funding Round, Seed, Convertible Note
- Switzerland
Portfolio highlights
- Occlufit — Occlufit is an occluder device that conforms to complex geometries and provides immediate sealing of cardiovascular defects.
- Navignostics — Navignostics combines highly multiplex tumor imaging with advanced data analytics for personalized cancer treatments.
- ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
The University of Zurich is one of the leading research universities in Europe and offers the widest range of degree programs in Switzerland.
Show more
Investment focus
- Health Care, Life Science, Biotechnology
- Series A
- Switzerland
Portfolio highlights
- MUVON Therapeutics — Muvon Therapeutics platform helps women with urinary incontinence and treats diseases based on skeletal muscle degradation, supporting them in their commitment to living a healthy life. The company's mode of contact is by mail, phone, and physical address.
VENTURE We invest across all sectors with specific focus on technology and digital The largest independent more About Us Portfolio [...]
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series A, Series B, Series C
- Italy, Switzerland, United States
Portfolio highlights
- Nouscom — Nouscom is a next-generation immunotherapy company developing genetic cancer vaccines and oncolytic viruses..
- MicThera — MicThera focuses on developing microbial-derived therapeutics to provide effective treatments for prostate cancer patients, aiming to find effective solutions for medical companies.
- Easy Rain — We are Easyrain. Continuous innovation runs in our blood.With our expertise, we develop, simulate, and test solutions, launching our ideas into production. We exploit the basic laws of physics to engineer a tangible solution!
RH Capital a Rhia Ventures fund, is an impact-first venture capital firm that invests in early-stage startups with the potential to transform women's health and increase health equity.
Show more
Investment focus
- Health Care, Biotechnology, Health Diagnostics
- Funding Round
- United States
Portfolio highlights
- Novocuff — Novocuff is a medical device firm that aims to improve pregnancy outcomes and reduce preterm deliveries caused by PPROM and cervical shortening.
- Ocon Healthcare — OCON Healthcare innovates, develops, manufactures, and commercializes cutting-edge women’s health products based on our patented IUB™ (Intra Uterine Ball) proprietary platform. The IUB™, made from a super-elastic alloy Nitinol, is an ideal carrier for multiple drugs to the uterus to treat a variety of conditions.In addition to our flagshipproduct, the IUB™ Ballerine®, OCON healthcare is developing an innovative pipeline of products utilizing the IUB™ frame for indications such as abnormal uterine bleeding (AUB), heavy menstrual bleeding (HMS), myomas/fibroids, and infertility.
- Seven Starling — Seven Starling offers comprehensive online care for postpartum mental health. Take the free assessment to get started.
Think.Health invests as a boutique risk-taker in healthcare ventures. We continuously seek innovations and disruptive business models in digital healthcare, medical technologies and health service providers,
Show more
Investment focus
- Health Care, Biotechnology, Medical Device
- Seed, Series A, Series B
- Germany, United States, Switzerland
Portfolio highlights
- Vara — Vara develops a breast cancer screening platform powered by AI for radiologists, allowing them to focus on finding cancer early. While we provide. Vara also provides remote mammography reading services to those that lack the radiologists. Vara's mission is to make affordable diagnostics available all over the world by designing machinelearning-powered workflows that users love to work with.
- anvajo — Originally started at TU Dresden, anvajo can now look back on several years of innovative research and successful product development with uninterrupted growth. As part of the business expansion and ongoing team building, anvajo moved into its new headquarters in Dresden in January 2020. On 1300 m² practically all areas, including development,production and support functions are united under one roof.
- Navignostics — Navignostics combines highly multiplex tumor imaging with advanced data analytics for personalized cancer treatments.
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more
Investment focus
- Biotechnology, Health Care, Therapeutics
- Series B, Series A, Series C
- United States, Switzerland, United Kingdom
Portfolio highlights
- Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
- Exsilio Therapeutics — Exsilio's method is based on naturally occurring genetic elements that can accurately insert new genes into cells via RNA intermediate templates. Exsilio employs predictive in-silico modeling and wet lab-based experiments to create such elements for accurate insertion of therapeutic genes into safe harbor regions of disease-relevant cells.
- Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
EFI Lake Geneva Ventures is a seed and early-stage investment strategy based in Geneva, Switzerland. Founded in 2020, our mission is to foster innovation by investing at an early stage in fast-growing innovative Swiss companies in Technology, Life Sciences and Medtech.
Show more
Investment focus
- Health Care, Medical, Life Science
- Seed, Pre-Seed, Series B
- Switzerland, Germany
Portfolio highlights
- Hylomorph — Hylomorph is a clinical-stage medical device company developing innovative materials designed to transform the biocompatibility of implantable medical devices.
- FluoSphera — Fluosphera better predicts the effects of molecules through animal-free microphysiological systems, helping you to discover more efficient drugs with less adverse side effects.
- Seprify — Enabling sustainable products
Students run the whole VC operation and are supported by a strong network of mentors. S2S is organized as a cross-campus initiative (ETH Zurich, EPFL, HSG, UZH) that fosters collaboration between different existing entrepreneurial student organizations.
Show more
Investment focus
- Health Care, Information Technology, Software
- Pre-Seed, Funding Round, Convertible Note
- Switzerland, Germany
Portfolio highlights
- Rrreefs — Our mission is to regenerate degraded coral reefs at global scale - restoring rich marine biodiversity for a healthy ocean.
- Yuon Control — Yuon Control offers an advanced and predictive heating control system designed to optimize heating networks. It makes an effective contribution to CO2 reduction.
- Cotierra — Biochar made from agricultural residues in the tropics can become a gamechanger for farmers and climate change mitigation
As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The companyfocuses on unquoted emerging companies, with two-thirds are invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN).
Show more
Investment focus
- Biotechnology, Health Care, Medical
- Series B, Series C, Series A
- United States, Switzerland, China
Portfolio highlights
- Upstream Bio — Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma. Upstream Bio was founded in 2004 and was headquartered in the United States.
- Vicore Pharma — Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.
- Odyssey Therapeutics — Odyssey Therapeutics is developing innovative medicines to make extraordinary leaps in outcomes for patients with cancer inflammatory diseases
Skyviews Life Science is a privately held advisory company specialised in personalised health.
Show more
Investment focus
- Biotechnology, Food and Beverage, Medical
- Series B, Series A, Seed
- United States, Switzerland, United Kingdom
Portfolio highlights
- Volumina Medical — Volumina is active in the field of tissue engineering and develops injectable 3D scaffolds for the reconstruction of volumes of soft tissues (fat, muscles, glandular tissues, supporting and connective tissues) that have been lost after tumor ablation, disease, trauma, or for purely esthetically purposes.
- Tropic Biosciences — Tropic transforms agriculture with cutting-edge genetic innovation. Together, we're building a productive and sustainable future for growers.
- Vedanta Biosciences — Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Amboy Street Ventures focuses on sexual health and women’s health technology startups.
Amboy Street Ventures was founded in 2021 and was headquartered in Los Angeles, USA.
Show more
Investment focus
- Health Care, Women's, Biotechnology
- Series A, Seed, Funding Round
- United States
Portfolio highlights
- Evvy — Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their mission is to close the gender health gap by discovering and leveraging overlooked biomarkers in the female body — starting with the vaginal microbiome.
- Testmate Health — Testmate Health is a medtech startup and award-winning spin-off of University of Geneva (Switzerland). We have developed a smartphone compatible platform test kit that diagnoses any disease with an identifiable DNA or RNA sequence - without the need for a lab, providing results directly at home in minutes. Based on this platform, our firstsolution is the first rapid urine self-test for the four most common sexually transmitted diseases (STD). One million new STDs are diagnosed a day, and yet the best improvements to date still need a lab, with results taking up to 7 days to be ready. Our easy to use all-in-one-kit provides results in minutes, anywhere, at any time, and the result is scannable by a smartphone to enable people to immediately gain access to treatment – if needed. Further test-kits with other diseases are in the pipeline to empower users to skip the waiting room, and take charge of their health from home.
- Granata Bio — Granata Bio is a biopharma company focused on women's health and infertility. Our mission and focus is to create access for fertility patients by introducing new therapeutic solutions.
Climate protection through innovative technologies.
The Technology Fund offers loan guarantees to Swiss companies whose novel products contribute to a sustainable reduction in greenhouse gas emissions
Show more
Investment focus
- Information Technology, Software, Biotechnology
- Debt Financing, Grant, Seed
- Switzerland
Portfolio highlights
- FGen — FGen is a Swiss start-up company founded 2011 in Basel as a spin-off from the Department of Biosystems Science and Engineering of the ETH Zurich. As a contract reasearch organization we collaborate with partners from Biotech, Life Sciences, and Pharma in order to establish efficient bioprocesses and to develop new biopharmaceuticals.
- Calopad — Calopad, awarded by the Swiss Confederation, offers a unique and the most holistic solution in pain therapy and muscle regeneration. The therapeutic deep heat of 42 degrees solves any muscle pain, muscle tension, or muscle spasms of chronic patients in the long term and in a highly efficient way through new forms of therapy. With the associatedapp, Calopad brings the physiotherapist digitally into any user's home and enables personalized all-around care in real time - utterly independent of time and place. In the future, the modular design will make it possible to combine different therapies such as heat, cold, or light with just one device, opening up the possibility of new therapeutic successes.
- Selfrag — SELFRAG AG is specialized in the development of high voltage pulse power products, plants and systems for selective fragmentation of solid materials.
Founderful operates as a venture capital firm and a Switzerland’s leading pre-seed fund.
Show more
Investment focus
- Software, Artificial Intelligence, Information Technology
- Pre-Seed, Seed, Series A
- Switzerland, United Kingdom, Canada
Portfolio highlights
- 8links — Advanced Battery Tech at Scale with 8inks: Revolutionize cell design, manufacturing, and chemistry for TWh-level solutions .
- EthonAI — The EthonAI Manufacturing Analytics System is a powerful software suite to achieve operational excellence at scale.
- Anthropos — Anthropos is your career platform designed for individuals and companies to manage their careers at scale, inside and outside organizations.
The Helm is the place to discover, shop, and fund female-identifying entrepreneurs.
Show more
Investment focus
- Health Care, Communities, E-Commerce
- Seed, Funding Round, Series A
- United States, Switzerland
Portfolio highlights
- Sway — Sway offers regenerative design solutions for plastic pollution using seaweed to create compostable replacements for single-use plastics. The company was co-founded by Julia Marsh, Matt Mayes, and Leland Maschmeyer and is headquartered in San Francisco, California, United States.
- Testmate Health — Testmate Health is a medtech startup and award-winning spin-off of University of Geneva (Switzerland). We have developed a smartphone compatible platform test kit that diagnoses any disease with an identifiable DNA or RNA sequence - without the need for a lab, providing results directly at home in minutes. Based on this platform, our firstsolution is the first rapid urine self-test for the four most common sexually transmitted diseases (STD). One million new STDs are diagnosed a day, and yet the best improvements to date still need a lab, with results taking up to 7 days to be ready. Our easy to use all-in-one-kit provides results in minutes, anywhere, at any time, and the result is scannable by a smartphone to enable people to immediately gain access to treatment – if needed. Further test-kits with other diseases are in the pipeline to empower users to skip the waiting room, and take charge of their health from home.
- itselectric — Itselectric partners with city property owners to unlock access to untapped electricity supply while they earn passive income.
Heritage Bank
Show more
Investment focus
- Biopharma, Life Science
- Seed
- Switzerland
Portfolio highlights
- Lagosta — WHAT WE DO. At LAGOSTA, we take great care in sustainably farming the European spiny lobster, converting byproducts in unique highly valuable products and setting up a series of ecological programs. Accelerated depletion of wild stocks due to overfishing and
Investors by industry
Energy
Climate
Health Care
Gaming
Hardware
Artificial intelligence
Impact
Proptech
Marketplace
Community
FinTech
Google
Consumer
Biotech
EdTech
Sustainability
Venture Capital
Beauty
Social Media
B2B
Medical
Email
Art
Photography
Wellness
Music
Mobile
Franchise
Social Network
Finance
Local
Internet
Digital Media
Construction
Manufacturing
Real Estate
eSports
Sports
Enterprise Software
Legal
Android
Big Data
Platforms
Mobile Advertising
Biotechnology
Hospitality
Fitness
Travel
Recruiting
Cannabis
Wine And Spirits
Medical Device
Crowdfunding
Social
Automotive
Web3
CleanTech
Transportation
Mobile Apps
Clean Energy
InsurTech
Enterprise
Oil and Gas
Video Games
Food and Beverage
Publishing
LGBT
Education
Payments
Fashion
Organic Food
Retail
Financial Services
Infrastructure
Life Science
Theatre
Film
Sporting Goods
Non Profit
Renewable Energy
SaaS
Software
Restaurants
Social Impact
Celebrity
Cryptocurrency
Blockchain
Agriculture (agtech)
Media (entertainment)
Facebook
Investors by country
India
Germany
South Korea
United Kingdom
Australia
Ireland
New Zealand
Canada
United States
Spain
Indonesia
Singapore
South Africa
Africa
Qatar
Europe
LATAM
Middle East
Sri Lanka
Asia
Armenia
Vietnam
China
Japan
Saudi Arabia
Brazil
Oceania
Czech Republic
Ecuador
Morocco
Barbados
Malta
Costa Rica
Mali
Malaysia
Finland
Italy
Belarus
Peru
France
Lithuania
Estonia
Myanmar
Lebanon
Kuwait
Hong Kong
Cayman Islands
Cambodia
Israel
Panama
Denmark
Mexico
Gibraltar
Kazakhstan
Liberia
Jersey
Philippines
Chile
Norway
Mauritius
Bermuda
Belize
Georgia
Kenya
Greece
Liechtenstein
Nicaragua
Egypt
Turkey
Serbia
Rwanda
Hungary
El Salvador
Venezuela
Ukraine
Ethiopia
Faroe Islands
Algeria
Portugal
Sierra Leone
Zimbabwe
Ghana
Sweden
Taiwan
Senegal
Belgium
Uruguay
Uganda
Croatia
Tunisia
San Marino
Slovenia
Zambia
Bulgaria
Uzbekistan
Russian Federation
Seychelles
Thailand
Bahrain
Puerto Rico
Tajikistan
Togo
Dominican Republic
Poland
Nigeria
Tanzania
United Arab Emirates
Honduras
Bolivia
Azerbaijan
Isle of Man
Namibia
Luxembourg
Iceland
Albania
Pakistan
Iraq
Bahamas
Grenada
Jordan
Romania
Argentina
Bangladesh
Latvia
Cyprus
Oman
Austria
Cameroon
Switzerland
Marshall Islands
Colombia
Guatemala
VC (Venture Capital) Funds in Switzerland by industry
Crowdfunding
Venture Capital
Film
Transportation
eSports
Financial Services
Big Data
Cryptocurrency
Education
Payments
Food and Beverage
Mobile Apps
Medical
Video Games
Wellness
Medical Device
Sports
Fitness
Email
Hardware
Social Media
Digital Media
Organic Food
Manufacturing
Internet
Music
Android
Blockchain
Mobile
Construction
Software
Legal
Automotive
Hospitality
InsurTech
Travel
Recruiting
Biotechnology
Platforms
FinTech
Enterprise
Consumer
Health Care
Biotech
Climate
Energy
Sustainability
Impact
Proptech
SaaS
Marketplace
Gaming
Artificial intelligence
Community
Retail
Social
Infrastructure
Fashion
B2B
Life Science
Publishing
Sporting Goods
Oil and Gas
Clean Energy
Finance
Renewable Energy
Real Estate
Web3
Non Profit
Social Network
EdTech
Restaurants
Media (entertainment)
Social Impact
Agriculture (agtech)
Mobile Advertising
Enterprise Software
CleanTech